NewAmsterdam Pharma (NAMSW) Stock Analysis

What NewAmsterdam Pharma does

NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.

Key metrics

ETFs linked to NAMSW

Broad-market and Healthcare sector ETFs an investor holding NewAmsterdam Pharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how NAMSW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for NewAmsterdam Pharma?

NewAmsterdam Pharma trades under the ticker NAMSW on NASDAQ.

Which exchange is NAMSW listed on?

NAMSW is listed on NASDAQ.

What sector does NewAmsterdam Pharma operate in?

NewAmsterdam Pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze NAMSW in a portfolio?

PortView shows NAMSW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.